Moderna (MRNA) and Merck (MRK) cancer vaccine sustains benefit at five years, but investors stay cautious

Moderna, Inc. (NASDAQ: MRNA) and Merck & Co., Inc. (NYSE: MRK) reported durable five-year data for their personalized mRNA cancer vaccine, a genuine scientific milestone that nonetheless failed to lift either stock. The treatment, intismeran autogene, also known as mRNA-4157 or V940, combined with Merck’s blockbuster immunotherapy Keytruda, continued to reduce the risk of cancer recurrence or death by 49 percent compared with Keytruda alone in patients with high-risk melanoma who had undergone surgery. Crucially, that benefit held steady from the three-year mark to five years, demonstrating a lasting effect for one of the most closely watched programs in oncology. Yet Moderna shares fell about 2.4 percent and Merck slipped as well, a muted reaction that captures the gap between long-term scientific promise and the near-term concerns weighing on each company. The results validate the mRNA cancer vaccine platform, but pivotal Phase 3 data and any approval remain years away.

What did the five-year Moderna and Merck mRNA cancer vaccine data actually show?

The headline result was durability rather than a new efficacy signal. The five-year follow-up from the Phase 2b KEYNOTE-942 study showed that adding intismeran autogene to Keytruda reduced the risk of recurrence or death by 49 percent versus Keytruda alone in patients with resected high-risk stage III and IV melanoma. That figure was essentially identical to the benefit reported at three years, demonstrating what oncologists call a maintenance of effect.

The depth of the benefit extended beyond recurrence. Earlier readouts and the longer follow-up also pointed to a meaningful reduction in the risk of cancer spreading to distant parts of the body, a secondary measure that matters because distant metastasis is the most dangerous form of recurrence. Sustained protection on both fronts strengthens the clinical case that the combination changes the disease course rather than merely delaying it briefly.

The historic significance lies in the platform. This program produced the first demonstration that an mRNA-based cancer treatment can work in a randomized clinical trial, and the five-year data show that the early promise was not a fluke. For a field that has long sought to turn the body’s immune system against cancer through vaccination, durable results at five years are a landmark, even if the market reaction was subdued.

How does the personalized mRNA cancer vaccine work alongside Merck’s Keytruda?

The treatment is genuinely individualized, which is what makes it novel. Intismeran autogene is a lipid-encapsulated mRNA therapy custom-built for each patient, encoding up to 34 neoantigens, the unique mutation signatures of that person’s own tumor, selected by a proprietary algorithm. The vaccine is designed to train the immune system to recognize and attack cancer cells bearing those specific markers.

The combination with Keytruda is central to the strategy. Keytruda is Merck’s anti-PD-1 checkpoint inhibitor, which releases the brakes on the immune system, while the personalized vaccine directs newly activated T cells toward the patient’s specific tumor neoantigens. The two mechanisms are complementary, and the trial data suggest that pairing a vaccine with a checkpoint inhibitor produces a greater anti-tumor response than the checkpoint inhibitor alone.

The manufacturing model is both the breakthrough and the challenge. Producing a bespoke vaccine for every patient, based on sequencing their tumor, represents a significant logistical and scaling undertaking compared with off-the-shelf drugs. Moderna’s mRNA platform, refined during the pandemic, is what makes rapid individualized manufacturing conceivable, and success here would validate that platform for a high-value oncology market well beyond infectious disease vaccines.

Why did Moderna stock fall despite the promising melanoma vaccine results?

The first reason is that the data confirmed expectations rather than surprising the market. Because the five-year result simply maintained the benefit already seen at three years, there was no new positive shock to drive the stock higher, and in a market that had partly priced in durability, a confirmation can trigger a sell-the-news reaction.

The second reason is the long timeline to any payoff. The vaccine remains in Phase 3 development, with pivotal trials in melanoma and lung cancer still enrolling and reading out over the coming years, so there is no near-term revenue attached to the program. Investors focused on the next several quarters get little immediate benefit from a catalyst that may not translate into sales until late in the decade.

The third and most pressing reason is Moderna’s near-term financial picture. The company is navigating a steep decline in COVID vaccine revenue, continues to post large losses, and is burning cash as it invests across its pipeline, leaving it deeply unprofitable on a per-share basis even with a substantial cash cushion. Against that backdrop, a promising but distant oncology catalyst does little to ease concerns about the immediate transition Moderna must execute, which is why the stock fell rather than rallied.

What does the durable data mean for Merck as Keytruda approaches its patent cliff?

For Merck, the vaccine is strategically important even though it is small relative to the company’s scale. Keytruda is the best-selling drug in the world and Merck’s central profit engine, but it faces loss of exclusivity toward the end of the decade, creating an urgent need to extend and defend the franchise. Combination regimens that pair Keytruda with novel agents are a core part of that life-cycle strategy.

The personalized vaccine fits that defensive logic. If intismeran autogene combined with Keytruda becomes a standard of care in melanoma and potentially lung cancer, it would create a differentiated regimen that is harder for biosimilar competitors to replicate, helping Merck retain patients and pricing power as the patent cliff approaches. The durability of the five-year data makes that scenario more credible.

The caveat is that the contribution is years away and uncertain. Merck is simultaneously pursuing many other strategies to offset the Keytruda cliff, and the vaccine is one bet among several, including next-generation cancer drugs and an experimental lung-cancer therapy of its own. Merck shares slipped alongside Moderna, partly reflecting separate company-specific news, which underscores that a single Phase 2b durability update does not materially move a company of Merck’s size on its own.

How are Moderna and Merck shares positioned amid their very different challenges?

The two companies enter this milestone from opposite positions. Moderna trades around 46 dollars within a wide 52-week range of roughly 22 to 60 dollars, with a market capitalization near 18 billion dollars, no debt, and a sizable cash balance, but deep losses as it transitions away from pandemic-era revenue. The stock is a high-volatility bet on its pipeline maturing before its cash and patience run thin.

Merck sits at the other end of the spectrum. The shares trade near 115 dollars within a 52-week range of about 75 to 125 dollars, supported by a market capitalization near 285 billion dollars and the enormous cash flows from Keytruda and a broad portfolio. Analyst sentiment on Merck is more measured than bullish, with hold ratings common and price targets around 125 dollars, reflecting the overhang of the looming patent cliff despite the company’s current strength.

The contrast frames how investors weigh the same data differently. For Moderna, the vaccine is a potential company-defining product that could transform its long-term value, which is why its stock is more sensitive to the program yet still pressured by near-term realities. For Merck, it is a valuable but incremental piece of a much larger puzzle. Neither stock rallied, but the reasons differ, and that divergence is the most telling part of the market’s response.

What clinical, regulatory and commercial risks remain for the cancer vaccine?

The first risk is the jump from Phase 2b to Phase 3. Mid-stage results, however durable, do not guarantee success in larger pivotal trials, and the history of oncology is littered with promising early data that failed to confirm in Phase 3. The ongoing melanoma and lung cancer studies must replicate the benefit in bigger, more rigorous trials before approval is possible.

The second risk is manufacturing and commercial scalability. A therapy individualized for each patient requires sequencing tumors and producing bespoke vaccines at scale, a complex and potentially costly process that must be made reliable and economical for broad use. Reimbursement for such personalized treatments is also untested at scale, and payers will scrutinize the cost relative to the benefit.

The third risk is competition and timing. The cancer immunotherapy field is intensely competitive, with numerous companies pursuing vaccines, cell therapies, and novel checkpoint combinations, and a multi-year path to market leaves room for rivals to advance. For now, the five-year data is a meaningful scientific validation of the mRNA cancer vaccine approach, but the muted stock reaction is a reminder that investors are weighing that long-term promise against the immediate financial and strategic pressures each company faces. The science took a real step forward, even if the market chose to wait.

Key takeaways on what the five-year vaccine data means for Moderna and Merck

• The personalized mRNA cancer vaccine intismeran autogene with Keytruda sustained a 49 percent reduction in recurrence or death at five years in high-risk melanoma, matching the three-year result.
• The data is the first to show durable five-year efficacy for an mRNA cancer treatment in a randomized setting, validating the platform.
• The vaccine is individualized, encoding up to 34 patient-specific neoantigens, and works by directing immune cells activated by Keytruda toward the tumor.
• Moderna shares fell about 2.4 percent because the result confirmed expectations, offers no near-term revenue, and does not address the company’s COVID-driven financial pressures.
• Moderna remains deeply unprofitable with a steep decline in pandemic-era sales, making distant catalysts less impactful for the stock.
• For Merck, the vaccine supports its strategy to defend the Keytruda franchise ahead of a late-decade patent cliff through differentiated combinations.
• Merck shares also slipped, reflecting separate news and the reality that one Phase 2b update barely moves a company of its size.
• Moderna trades near 46 dollars with a roughly 18 billion dollar market cap, while Merck trades near 115 dollars with a roughly 285 billion dollar market cap.
• Key risks include confirming the benefit in Phase 3, scaling complex individualized manufacturing, and intense competition in cancer immunotherapy.
• Pivotal melanoma and lung cancer trial results and any approval remain years away, explaining the cautious market response.